Holen Sie sich die Stockscreener-App
13.99
0.14%
0.02
Handel nachbörslich:
13.99
Schlusskurs vom Vortag:
$13.97
Offen:
$13.99
24-Stunden-Volumen:
735.88K
Relative Volume:
0.14
Marktkapitalisierung:
$1.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-4.2394
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
+0.79%
1M Leistung:
+51.08%
6M Leistung:
+339.94%
1J Leistung:
+582.44%
1-Tages-Spanne:
$13.97
$14.00
1-Wochen-Bereich:
$13.85
$14.06
52-Wochen-Spanne:
$0.783
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(760) 407-6511
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
13.99 | 1.00B | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Halper Sadeh LLC Encourages NATH, VTYX, SKYT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple - Yahoo Finance
Ventyx Biosciences (VTYX) Price Target Increased by 12.94% to 13.99 - MSN
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - yourwyominglink.com
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VTYX, ALEX, RVYL, and FFWM - Benzinga
Ventyx Biosciences approves cash bonus awards for executives ahead of planned merger - Investing.com Nigeria
Ventyx Biosciences approves cash bonus awards for executives ahead of planned merger By Investing.com - Investing.com South Africa
Ventyx Biosciences Sets Special Cash Bonuses Amid Lilly Merger - TipRanks
Institution Moves: Is Ventyx Biosciences Inc forming a double bottomQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Aug Update: Can Caledonia Mining Corporation Plc be the next market leaderMarket Rally & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Does Ventyx Biosciences Inc. meet Warren Buffett’s criteria2025 Trade Ideas & Expert Curated Trade Setups - baoquankhu1.vn
Halper Sadeh Investigates Ventyx and Sun Country Transactions - Intellectia AI
Market Fear: Will Ventyx Biosciences Inc stock hit new highs in YEAR2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (NasdaqSNCY), Ventyx Biosciences, Inc. (Nasdaq - GlobeNewswire Inc.
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Published on: 2026-01-21 17:52:30 - baoquankhu1.vn
Does Ventyx Biosciences Inc. stock reflect fundamentalsPortfolio Return Summary & Weekly Top Stock Performers List - bollywoodhelpline.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Short Interest Update - MarketBeat
Will Ventyx Biosciences Inc. stock split attract more investorsMarket Sentiment Summary & Entry Point Confirmation Alerts - bollywoodhelpline.com
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Strategizing Beyond Weight Management Drugs - Intellectia AI
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - Finviz
Halper Sadeh Investigates ON24, Ventyx, and Sun Country for Potential Violations - Intellectia AI
Risk Off: Can RAPT Therapeutics Inc benefit from deglobalizationJuly 2025 Spike Watch & Stepwise Swing Trade Plans - baoquankhu1.vn
Analyst Calls: Will Ventyx Biosciences Inc stock hit new highs in YEARQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion, Expanding Drug Pipeline - Intellectia AI
Citizens Financial Group Inc. RI Takes Position in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation - FinancialContent
Aug Sectors: What are Ventyx Biosciences Incs earnings expectationsWall Street Watch & Free Long-Term Investment Growth Plans - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - yourwyominglink.com
Daily Breeze - FinancialContent
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - Finviz
Halper Sadeh LLC Encourages VTYX, SNCY, EKSO Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Upcoming Events - FinancialContent
How This Newcomer Is Taking On Eli Lilly's $1.2 Billion Buyout - Investor's Business Daily
HC Wainwright Has Negative Estimate for VTYX FY2029 Earnings - MarketBeat
Eli Lilly and Company (LLY) to acquire Ventyx Biosciences - MSN
Ventyx Biosciences jumps on report Eli Lilly nears more than $1B deal - MSN
Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences - Insider Monkey
Lilly To Acquire California-Based Ventyx Biosciences For $1.2B - inkfreenews.com
Ventyx Biosciences (NASDAQ:VTYX) Rating Lowered to "Hold" at UBS Group - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Downgraded by Wells Fargo & Company to "Hold" - MarketBeat
Key facts: Eli Lilly to acquire Ventyx for $1.2B; Mounjaro pricing in India; AI partnership with Revvity - TradingView — Track All Markets
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences - FinancialContent
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - Dealbreaker
Ventyx Biosciences (NASDAQ:VTYX) Rating Lowered to "Hold" at Lifesci Capital - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Downgraded to Hold Rating by Clear Str - MarketBeat
Ventyx Biosciences (VTYX) Downgraded by Wells Fargo to Equal-Wei - GuruFocus
Ventyx Biosciences to be Sold to Eli Lilly for $14 per Share - Intellectia AI
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Invest - GuruFocus
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ventyx Biosciences Inc-Aktie (VTYX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Dec 18 '25 |
Sale |
7.72 |
47,345 |
365,461 |
2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 17 '25 |
Option Exercise |
0.00 |
34,930 |
0 |
502,156 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 18 '25 |
Sale |
7.72 |
12,675 |
97,840 |
489,481 |
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):